Pioglitazone, the agonist of PPARγ, ameliorates mitochondrial disorders, reduces lipid deposition during, and thus prevents against severe pulmonary arterial hypertension and vascular remodeling (49). Here, PPARG is linked to pulmonary arterial hypertension.